MEVIS MEDICAL SOLUTIONS AG (M3V.DE) Fundamental Analysis & Valuation

FRA:M3V • DE000A0LBFE4

Current stock price

22.8 EUR
0 (0%)
Last:

This M3V.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. M3V.DE Profitability Analysis

1.1 Basic Checks

  • In the past year M3V was profitable.
  • M3V had a positive operating cash flow in the past year.
  • Each year in the past 5 years M3V has been profitable.
  • Each year in the past 5 years M3V had a positive operating cash flow.
M3V.DE Yearly Net Income VS EBIT VS OCF VS FCFM3V.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

1.2 Ratios

  • M3V's Return On Assets of 17.22% is amongst the best of the industry. M3V outperforms 100.00% of its industry peers.
  • Looking at the Return On Equity, with a value of 25.58%, M3V belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • The Return On Invested Capital of M3V (14.00%) is better than 100.00% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for M3V is significantly above the industry average of 8.24%.
Industry RankSector Rank
ROA 17.22%
ROE 25.58%
ROIC 14%
ROA(3y)19.91%
ROA(5y)19.35%
ROE(3y)32.29%
ROE(5y)30.88%
ROIC(3y)17.15%
ROIC(5y)17.35%
M3V.DE Yearly ROA, ROE, ROICM3V.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

  • The Profit Margin of M3V (26.87%) is better than 83.33% of its industry peers.
  • M3V's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 23.58%, M3V belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
  • In the last couple of years the Operating Margin of M3V has declined.
  • Looking at the Gross Margin, with a value of 97.12%, M3V belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
  • M3V's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 23.58%
PM (TTM) 26.87%
GM 97.12%
OM growth 3Y-4.71%
OM growth 5Y-9.81%
PM growth 3Y-1.4%
PM growth 5Y-9.66%
GM growth 3Y-0.07%
GM growth 5Y-0.07%
M3V.DE Yearly Profit, Operating, Gross MarginsM3V.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. M3V.DE Health Analysis

2.1 Basic Checks

  • M3V has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for M3V remains at a similar level compared to 1 year ago.
  • M3V has about the same amout of shares outstanding than it did 5 years ago.
  • M3V has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
M3V.DE Yearly Shares OutstandingM3V.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
M3V.DE Yearly Total Debt VS Total AssetsM3V.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • M3V has an Altman-Z score of 4.40. This indicates that M3V is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 4.40, M3V belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
  • M3V has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.4
ROIC/WACC1.88
WACC7.45%
M3V.DE Yearly LT Debt VS Equity VS FCFM3V.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 1.52 indicates that M3V should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.52, M3V is in line with its industry, outperforming 50.00% of the companies in the same industry.
  • A Quick Ratio of 1.52 indicates that M3V should not have too much problems paying its short term obligations.
  • M3V has a Quick ratio (1.52) which is in line with its industry peers.
  • M3V does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.52
Quick Ratio 1.52
M3V.DE Yearly Current Assets VS Current LiabilitesM3V.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. M3V.DE Growth Analysis

3.1 Past

  • M3V shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.41%.
  • Measured over the past years, M3V shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -10.74% on average per year.
  • The Revenue has decreased by -2.14% in the past year.
  • The Revenue has been decreasing by -1.25% on average over the past years.
EPS 1Y (TTM)-7.41%
EPS 3Y0.13%
EPS 5Y-10.74%
EPS Q2Q%-38.82%
Revenue 1Y (TTM)-2.14%
Revenue growth 3Y1.53%
Revenue growth 5Y-1.25%
Sales Q2Q%-7.59%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
M3V.DE Yearly Revenue VS EstimatesM3V.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
M3V.DE Yearly EPS VS EstimatesM3V.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

5

4. M3V.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 9.12 indicates a reasonable valuation of M3V.
  • 100.00% of the companies in the same industry are more expensive than M3V, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 25.23, M3V is valued rather cheaply.
Industry RankSector Rank
PE 9.12
Fwd PE N/A
M3V.DE Price Earnings VS Forward Price EarningsM3V.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • M3V's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. M3V is cheaper than 75.00% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, M3V is valued a bit cheaper than the industry average as 66.67% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 14.59
EV/EBITDA 8.46
M3V.DE Per share dataM3V.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

  • The excellent profitability rating of M3V may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. M3V.DE Dividend Analysis

5.1 Amount

  • M3V has a Yearly Dividend Yield of 3.63%.
  • M3V's Dividend Yield is a higher than the industry average which is at 2.15.
  • Compared to an average S&P500 Dividend Yield of 1.90, M3V pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.63%

5.2 History

  • The dividend of M3V is nicely growing with an annual growth rate of 24.89%!
Dividend Growth(5Y)24.89%
Div Incr Years0
Div Non Decr Years0
M3V.DE Yearly Dividends per shareM3V.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2024 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

  • 107.89% of the earnings are spent on dividend by M3V. This is not a sustainable payout ratio.
  • M3V's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
DP107.89%
EPS Next 2YN/A
EPS Next 3YN/A
M3V.DE Yearly Income VS Free CF VS DividendM3V.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
M3V.DE Dividend Payout.M3V.DE Dividend Payout, showing the Payout Ratio.M3V.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

M3V.DE Fundamentals: All Metrics, Ratios and Statistics

MEVIS MEDICAL SOLUTIONS AG

FRA:M3V (3/26/2026, 7:00:00 PM)

22.8

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)01-29
Earnings (Next)05-21
Inst Owners23.29%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap41.50M
Revenue(TTM)16.97M
Net Income(TTM)4.56M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.63%
Yearly Dividend2.7
Dividend Growth(5Y)24.89%
DP107.89%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 9.12
Fwd PE N/A
P/S 2.45
P/FCF 14.59
P/OCF 13.19
P/B 2.33
P/tB 2.33
EV/EBITDA 8.46
EPS(TTM)2.5
EY10.96%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.56
FCFY6.85%
OCF(TTM)1.73
OCFY7.58%
SpS9.32
BVpS9.79
TBVpS9.79
PEG (NY)N/A
PEG (5Y)N/A
Graham Number23.47
Profitability
Industry RankSector Rank
ROA 17.22%
ROE 25.58%
ROCE 19.88%
ROIC 14%
ROICexc 20.72%
ROICexgc 20.72%
OM 23.58%
PM (TTM) 26.87%
GM 97.12%
FCFM 16.76%
ROA(3y)19.91%
ROA(5y)19.35%
ROE(3y)32.29%
ROE(5y)30.88%
ROIC(3y)17.15%
ROIC(5y)17.35%
ROICexc(3y)27.89%
ROICexc(5y)26.51%
ROICexgc(3y)27.89%
ROICexgc(5y)26.51%
ROCE(3y)24.36%
ROCE(5y)24.64%
ROICexgc growth 3Y-4.16%
ROICexgc growth 5Y-6.12%
ROICexc growth 3Y-4.16%
ROICexc growth 5Y-6.1%
OM growth 3Y-4.71%
OM growth 5Y-9.81%
PM growth 3Y-1.4%
PM growth 5Y-9.66%
GM growth 3Y-0.07%
GM growth 5Y-0.07%
F-Score4
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 227.51%
Cap/Sales 1.78%
Interest Coverage 250
Cash Conversion 76.1%
Profit Quality 62.38%
Current Ratio 1.52
Quick Ratio 1.52
Altman-Z 4.4
F-Score4
WACC7.45%
ROIC/WACC1.88
Cap/Depr(3y)151.22%
Cap/Depr(5y)111.1%
Cap/Sales(3y)0.98%
Cap/Sales(5y)0.77%
Profit Quality(3y)80.13%
Profit Quality(5y)97.8%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.41%
EPS 3Y0.13%
EPS 5Y-10.74%
EPS Q2Q%-38.82%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-2.14%
Revenue growth 3Y1.53%
Revenue growth 5Y-1.25%
Sales Q2Q%-7.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.41%
EBIT growth 3Y-3.25%
EBIT growth 5Y-10.94%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-50.74%
FCF growth 3Y-32.08%
FCF growth 5Y-14.82%
OCF growth 1Y-46.25%
OCF growth 3Y-29.89%
OCF growth 5Y-13.63%

MEVIS MEDICAL SOLUTIONS AG / M3V.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MEVIS MEDICAL SOLUTIONS AG (M3V.DE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to M3V.DE.


What is the valuation status for M3V stock?

ChartMill assigns a valuation rating of 5 / 10 to MEVIS MEDICAL SOLUTIONS AG (M3V.DE). This can be considered as Fairly Valued.


How profitable is MEVIS MEDICAL SOLUTIONS AG (M3V.DE) stock?

MEVIS MEDICAL SOLUTIONS AG (M3V.DE) has a profitability rating of 8 / 10.


What is the financial health of MEVIS MEDICAL SOLUTIONS AG (M3V.DE) stock?

The financial health rating of MEVIS MEDICAL SOLUTIONS AG (M3V.DE) is 9 / 10.